Research Associate / Research Fellow in Radiochemistry (radiometals and chelators)
The role is to perform radiopharmaceutics research and provide specialist expertise as a chemist within a multidisciplinary EPSRC-funded Programme: Next Generation Radiochemistry for Molecular Imaging with Radionuclides (MITHRAS), based at King’s College London, Imperial College and the University of Southampton. The team will include specialists in radionuclide production, nanodrug and cell therapy researchers, organic and inorganic radiochemists, and molecular imaging biologists, and will be embedded within a wider collaborative network comprising the Imaging Chemistry and Biology Department and the School of Biomedical Engineering and Imaging Sciences at King’s, and a network of major internal and external collaborations with other major London universities and hospitals. The aim of the programme is to develop new chemistry for fast, accessible synthesis of radiopharmaceuticals, and translate this into clinically translatable products for imaging and radionuclide therapy.
This post holder will have the specific role of developing new radiometal chemistry i.e. designing ligands for a range of new and existing radiometals that will be subjected to preclinical evaluation.
We are looking for someone with a range of synthetic chemistry (inorganic and organic) and ideally, radiochemistry skills or experience in imaging sciences. This role will encompass varied responsibilities, including work on a wide range of collaborative projects. The post holder will develop new chemistry and chelators and use them to develop radiometal-based radiopharmaceuticals including complexes and bioconjugates, incorporating a range of different radiometals. In addition, the post holder will perform preclinical research in radiopharmaceutics including in vitro and in vivo biological studies and preclinical molecular imaging (mainly PET, SPECT, CT, but also potentially optical and MR). This work will involve collaborations with research groups across King’s, Imperial and Southampton to drive the development and translation of radionuclide-based molecular imaging and therapy agents.